Genetic variants of interferon-stimulated genes and IL-28B as host prognostic factors of response to combination treatment for chronic hepatitis C

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 5, 2011, Pages 712-721

  Lopez Rodriguez, R ^a   Trapero Marugan, M ^a   Borque, M J ^a   Roman, M ^a   Hernandez Bartolome, A ^a   Rodriguez Muoz Y ^a   Martin Vilchez, S ^a   Abad Santos, F ^a   Muoz De Rueda P ^b   Vidal Castieira J R ^c   Rodrigo, L ^c   Salmeron, J ^b   Moreno Otero, R ^a   Sanz Cameno, P ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON RECEPTOR; ALPHA INTERFERON RECEPTOR 1; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; INTERFERON; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B; PROTEIN INHIBITOR OF ACTIVATED STAT; RIBAVIRIN; STAT1 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR IFIT1; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENETIC VARIATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERFERONS; INTERLEUKINS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 80054990153     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.189     Document Type: Article

References (39)

1. Brown, R.S. Hepatitis C and liver transplantation. Nature 436, 973-978 (2005).
2. Feld, J.J. & Hoofnagle, J.H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436, 967-972 (2005). (Pubitemid 41191673)
3. Ghany, M.G., Strader, D.B., Thomas, D.L. & Seeff, L.B.; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49, 1335-1374 (2009).
4. Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399-401 (2009).
5. Suppiah, V. et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 41, 1100-1104 (2009).
6. Tanaka, Y. et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41, 1105-1109 (2009).
7. Rauch, A. et al.; Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138, 1338-45, 1345.e1 (2010).
8. Thomas, D.L. et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461, 798-801 (2009).
9. McCarthy, J.J. et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 138, 2307-2314 (2010).
10. Thompson, A.J. et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 139, 120-9.e18 (2010).
11. Sen, G.C. Viruses and interferons. Annu. Rev. Microbiol. 55, 255-281 (2001). (Pubitemid 32978106)
12. Dill, M.T. et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 140, 1021-1031 (2011).
13. Su, X. et al.; Virahep-C Study Group. Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferonstimulated genes with the response to interferon therapy for chronic hepatitis C. J. Hepatol. 49, 184-191 (2008).
14. Welzel, T.M. et al.; HALT-C Trial Group. Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 49, 1847-1858 (2009).
15. Asselah, T. et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 57, 516-524 (2008).
16. Honda, M. et al.; Hokuriku Liver Study Group. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 139, 499-509 (2010).
17. Chen, L. et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128, 1437-1444 (2005). (Pubitemid 40712193)
18. Feld, J.J. et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 46, 1548-1563 (2007). (Pubitemid 350155537)
19. Sarasin-Filipowicz, M. et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl. Acad. Sci. USA 105, 7034-7039 (2008). (Pubitemid 351754525)
20. Hovanessian, A.G. & Justesen, J. The human 2′- 5′oligoadenylate synthetase family: unique interferon-inducible enzymes catalyzing 2′-5′?instead of 3′-5′ phosphodiester bond formation. Biochimie 89, 779-788 (2007). (Pubitemid 47001635)
21. Andersen, J.B., Strandbygård, D.J., Hartmann, R. & Justesen, J. Interaction between the 2′-5′oligoadenylate synthetase-like protein p59 OASL and the transcriptional repressor methyl CpG-binding protein 1. Eur. J. Biochem. 271, 628-636 (2004). (Pubitemid 38183637)
22. Ishibashi, M., Wakita, T. & Esumi, M. 2′,5′- Oligoadenylate synthetase-like gene highly induced by hepatitis C virus infection in human liver is inhibitory to viral replication in vitro. Biochem. Biophys. Res. Commun. 392, 397-402 (2010).
23. Hartmann, R. et al. Activation of 2′-5′oligoadenylate synthetase by singlestranded and double-stranded RNA aptamers. J. Biol. Chem. 273, 3236-3246 (1998). (Pubitemid 28109734)
24. Rebouillat, D. & Hovanessian, A.G. The human 2′,5′- oligoadenylate synthetase family: interferon-induced proteins with unique enzymatic properties. J. Interferon Cytokine Res. 19, 295-308 (1999). (Pubitemid 29210677)
25. Yakub, I., Lillibridge, K.M., Moran, A., Gonzalez, O.Y., Belmont, J., Gibbs, R.A. et al. Single nucleotide polymorphisms in genes for 2′-5′-oligoadenylate synthetase and RNase L inpatients hospitalized with West Nile virus infection. J. Infect. Dis. 192, 1741-1748 (2005). (Pubitemid 41587824)
26. Luo, S., Cassidy, W., Jeffers, L., Reddy, K.R., Bruno, C. & Howell, C.D. Interferonstimulated gene expression in black and white hepatitis C patients during peginterferon alfa-2a combination therapy. Clin. Gastroenterol. Hepatol. 3, 499-506 (2005). (Pubitemid 40616916)
27. Guo, J., Peters, K.L. & Sen, G.C. Induction of the human protein P56 by interferon, double-stranded RNA, or virus infection. Virology 267, 209-219 (2000). (Pubitemid 30123603)
28. Terenzi, F., Hui, D.J., Merrick, W.C. & Sen, G.C. Distinct induction patterns and functions of two closely related interferon-inducible human genes, ISG54 and ISG56. J. Biol. Chem. 281, 34064-34071 (2006). (Pubitemid 46036616)
29. Wacher, C. et al. Coordinated regulation and widespread cellular expression of interferon-stimulated genes (ISG) ISG-49, ISG-54, and ISG-56 in the central nervous system after infection with distinct viruses. J. Virol. 81, 860-871 (2007). (Pubitemid 46067911)
30. Wang, C. et al. Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J. Virol. 77, 3898-3912 (2003). (Pubitemid 36350931)
31. Li, Y. et al. ISG56 is a negative-feedback regulator of virus-triggered signaling and cellular antiviral response. Proc. Natl. Acad. Sci. USA 106, 7945-7950 (2009).
32. Minamoto, S. et al. Cloning and functional analysis of new members of STAT induced STAT inhibitor (SSI) family: SSI-2 and SSI-3. Biochem. Biophys. Res. Commun. 237, 79-83 (1997). (Pubitemid 27390327)
33. Persico, M. et al. Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C. Gut 57, 507-515 (2008). (Pubitemid 351442535)
34. Huang, Y. et al. Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. Gastroenterology 132, 733-744 (2007). (Pubitemid 46274665)
35. Kim, K.A. et al. Hepatic SOCS3 expression is strongly associated with nonresponse to therapy and race in HCV and HCV/HIV infection. J. Hepatol. 50, 705-711 (2009).
36. Naka, T. et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 387, 924-929 (1997). (Pubitemid 27289596)
37. Abe, H. et al. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J. Hepatol. 53, 439-443 (2010).
38. de Rueda, P.M. et al. Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin. Am. J. Gastroenterol. 106, 1246-1254 (2011).
39. Solé, X., Guinó, E., Valls, J., Iniesta, R. & Moreno, V. SNPStats: a web tool for the analysis of association studies. Bioinformatics 22, 1928-1929 (2006). (Pubitemid 44283043)